Navigation Links
New Studies Demonstrate Clinical Utility and Validity of CancerType ID® Molecular Classifier
Date:3/22/2012

VANCOUVER, Canada, March 21, 2012  – bioTheranostics, Inc. announced today findings from three key studies. Results, presented at the United States and Canadian Academy of Pathology (USCAP) annual meeting, showed that CancerTYPE ID® had strong clinical utility and demonstrated a high level of accuracy for tumor classification and sub-classification. Tumor classification and sub-classification are important criteria in treatment selection with the advent of site- and subtype-specific therapies.

CancerTYPE ID is a standardized, objective, 92-gene molecular cancer classifier that classifies a broad range of distinct tumors by matching the gene expression pattern of a patient's tumor to a database of gene expression information from known tumor types and subtypes.

In a large retrospective analysis (USCAP 2012 Abstract # 429), researchers found that current immunohistochemistry (IHC) practices are non-standardized in protocol, interpretation and in time to completion, further underscoring a significant need for additional analytical approaches to aid in resolving indeterminate and differential diagnoses. Results indicate that more than seven IHC stains were associated with longer-than-average time to diagnosis but were not associated with increased diagnostic resolution.

The researchers further noted that an assay database with broad tumor coverage would be an important consideration for clinicians, as CancerTYPE ID predicted 23 main tumor types and 42 subtypes in the 754 cases reviewed.

In a second study, a multi-institutional analysis and the most comprehensive validation of a molecular classifier to date, CancerTYPE ID demonstrated excellent performance for classification of a diverse set of tumors (USCAP 2012 Abstract # 1888) that was consistent with previous validation results. The study reviewed 790 cases in collaboration with the Mayo Clinic, the University of California, Los Angeles (UCLA) and Massachusetts General Hospital (MGH).

The same researchers also evaluated the use of CancerTYPE ID to predict the site of origin for primary and metastatic tumors with neuroendocrine differentiation (USCAP 2012 Abstract # 604). Findings from this analysis indicated CancerTYPE ID may address an unmet medical need as a molecular correlate for sub-typing neuroendocrine tumors. The ability to subtype neuroendocrine tumors, among the most difficult to determine, has important implications for grading, staging and disease management.

"The 92-gene classifier demonstrated excellent accuracy for subtyping tumors with neuroendocrine differentiation," said Mark Erlander, PhD, Chief Scientific Officer of bioTheranostics. "While these results were part of a larger parent study designed to characterize performance of the classifier in a broad range of tumor histologies, these findings show promise for use of the 92-gene assay in classifying neuroendocrine tumors of uncertain primary site."

"In these recent studies, CancerTYPE ID's accuracy was also noted in both metastatic as well as poorly differentiated primary tumors, and its diagnostic value was maintained even in situations where there was limited tissue," said Richard Ding, Chief Executive Officer of bioTheranostics. "We believe this is an important step in discovering where a molecular classifier, such as CancerTYPE ID, fits in the diagnostic picture as an accurate, objective and time-saving adjunctive pathology asset. We appreciate the independent and growing support from pathologists in utilizing CancerTYPE ID as a standardized diagnostic aid in their workup of metastatic cancers."

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: breastcancerindex, which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; and CancerTYPE ID, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin. For more information, call 1-858-587-5870 or visit www.bioTheranostics.com.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for more than 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached euro 1.427 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com

FOR INFORMATION:

bioTheranostics
Tim Schofield
Tel: + 1 858 587 5890
tim.schofield@biotheranostics.com

bioMerieux
Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14
media@eu.biomerieux.com


'/>"/>
SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):